BindingDB logo
myBDB logout

BDBM419189 N-(4-ethylphenyl)-4-(((3- hydroxycyclobutyl)methyl) amino)-N-isobutyl-3-(S- methylsulfonimidoyl)benzene- sulfonamide::US10457637, Compound 61

SMILES: CCc1ccc(cc1)N(CC(C)C)S(=O)(=O)c1ccc(NCC2CC(O)C2)c(c1)S(C)(=N)=O

InChI Key: InChIKey=VOINJTNXBDANMG-UHFFFAOYSA-N

Data: 2 IC50

Find this compound or compounds like it in BindingDB:
Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 419189   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kcal/mole
IC50
nM
Kd
nM
EC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Interleukin-17A


(Homo sapiens (Human))
BDBM419189
PNG
(N-(4-ethylphenyl)-4-(((3- hydroxycyclobutyl)methyl...)
Show SMILES CCc1ccc(cc1)N(CC(C)C)S(=O)(=O)c1ccc(NCC2CC(O)C2)c(c1)S(C)(=N)=O
Show InChI InChI=1S/C24H35N3O4S2/c1-5-18-6-8-20(9-7-18)27(16-17(2)3)33(30,31)22-10-11-23(24(14-22)32(4,25)29)26-15-19-12-21(28)13-19/h6-11,14,17,19,21,25-26,28H,5,12-13,15-16H2,1-4H3
PDB

Reactome pathway

UniProtKB/SwissProt

GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isol...


US Patent US10457637 (2019)


BindingDB Entry DOI: 10.7270/Q2WS8WMG
More data for this
Ligand-Target Pair
Nuclear receptor ROR-gamma (RORC)


(Homo sapiens (Human))
BDBM419189
PNG
(N-(4-ethylphenyl)-4-(((3- hydroxycyclobutyl)methyl...)
Show SMILES CCc1ccc(cc1)N(CC(C)C)S(=O)(=O)c1ccc(NCC2CC(O)C2)c(c1)S(C)(=N)=O
Show InChI InChI=1S/C24H35N3O4S2/c1-5-18-6-8-20(9-7-18)27(16-17(2)3)33(30,31)22-10-11-23(24(14-22)32(4,25)29)26-15-19-12-21(28)13-19/h6-11,14,17,19,21,25-26,28H,5,12-13,15-16H2,1-4H3
PDB

Reactome pathway

UniProtKB/SwissProt
UniProtKB/TrEMBL

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a<100n/an/an/an/an/an/a



GALDERMA RESEARCH & DEVELOPMENT

US Patent


Assay Description
The RORγ transactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controll...


US Patent US10457637 (2019)


BindingDB Entry DOI: 10.7270/Q2WS8WMG
More data for this
Ligand-Target Pair